24 Mar HTx “Sandbox” workshop explores the practicalities of outcomes-based reimbursement agreements

HTx holds a follow-up ‘Policy Sandbox’ event to discuss the acceptability of outcomes-based agreements as a way of reimbursing high-cost innovative medicines.

Following a policy sandbox event in November 2022 to discuss the suitability of outcome-based agreements (OBAs) to support the sustainable reimbursement of advanced therapy medicinal products (ATMPs), HTx partners, led by the National Institute for Health and Care Excellence (United Kingdom), have held a follow-up event to explore some of the practical issues in more detail with key stakeholders.

On 22nd March 2023, the sandbox workshop was joined by 18 participants representing HTA organisations, payers, patients, and registries from across Europe. In session 1, the moderated discussion focused on identifying the key practical barriers and burdens associated with data collection from the perspectives of patients and healthcare providers. This was to identify features of OBAs that are desirable to minimise the burden on those groups. In session 2, the discussion turned to issues relating to value assessment and pricing, with participants exploring what HTA organisations can do to support interim pricing during data collection, and whether OBAs are always a suitable mechanism for supporting sustainable access to high-cost, complex medicines. 

The key messages will inform a list of principles for the planning and implementation of OBAs for innovative medicines to support HTA and decision-makers understand when and how to implement such agreements.